Weiss Multi-Strategy Advisers’s Intersect ENT, Inc XENT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-75,569
Closed -$2.12M 836
2022
Q1
$2.12M Hold
75,569
0.05% 398
2021
Q4
$2.06M Sell
75,569
-832
-1% -$22.5K 0.05% 383
2021
Q3
$2.08M Buy
76,401
+36,227
+90% +$896K 0.04% 404
2021
Q2
$687K Buy
40,174
+1,439
+4% +$26.9K 0.02% 531
2021
Q1
$809K Sell
38,735
-471
-1% -$10.9K 0.02% 510
2020
Q4
$898K Sell
39,206
-1,244
-3% -$23.7K 0.02% 501
2020
Q3
$660K Sell
40,450
-4,654
-10% -$84.3K 0.02% 455
2020
Q2
$611K Sell
45,104
-3,141
-7% -$36.5K 0.02% 453
2020
Q1
$572K Buy
48,245
+18,245
+61% +$405K 0.02% 337
2019
Q4
$747K Buy
30,000
+5,000
+20% +$101K 0.01% 512
2019
Q3
$425K Buy
+25,000
New +$455K 0.01% 504
2019
Q2
Sell
-10,000
Closed -$270K 672
2019
Q1
$322K Hold
10,000
0.01% 459
2018
Q4
$282K Buy
+10,000
New +$293K 0.01% 390
2018
Q3
Sell
-17,500
Closed -$655K 698
2018
Q2
$655K Buy
17,500
+7,500
+75% +$294K 0.02% 473
2018
Q1
$393K Buy
+10,000
New +$365K 0.01% 475

Weiss Multi-Strategy Advisers's XENT Position: Q2 2022 in Review

Weiss Multi-Strategy Advisers sold out of Intersect ENT, Inc (XENT) in Q2 2022, closing a stake of 75,569 shares — an estimated $2.12M sold.

Weiss Multi-Strategy Advisers first reported a position in XENT in Q1 2018 and held it in 15 quarters. The position peaked at $2.12M in Q1 2022. 0 funds tracked by Wall St. Rank hold XENT as of Q2 2022.

  • Weiss Multi-Strategy Advisers reported no remaining Intersect ENT, Inc position as of Q2 2022 after selling out during the quarter.
  • Weiss Multi-Strategy Advisers sold 75,569 Intersect ENT, Inc shares in Q2 2022, an estimated $2.12M.
  • Weiss Multi-Strategy Advisers first reported a position in Intersect ENT, Inc in Q1 2018 and held it in 15 quarters.
  • Weiss Multi-Strategy Advisers's Intersect ENT, Inc position peaked at $2.12M in Q1 2022.
  • 0 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q2 2022.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q2 2022, filed 15 Aug 2022.